STOCK TITAN

Ovid Therapeutics Inc - OVID STOCK NEWS

Welcome to our dedicated news page for Ovid Therapeutics (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ovid Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ovid Therapeutics's position in the market.

Rhea-AI Summary
Ovid Therapeutics Inc. reported positive progress in Phase 3 trials for soticlestat in treating Lennox-Gastaut syndrome and Dravet syndrome, with anticipated data readouts by September 2024. Financially, the company holds $105.8 million in cash, cash equivalents, and marketable securities as of December 31, 2023, supporting operations until the first half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
earnings
-
Rhea-AI Summary
Ovid Therapeutics Inc. (NASDAQ: OVID) to participate in a panel on 'Orphan Epilepsies' at the TD Cowen 44th Annual Health Care Conference. The live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.51%
Tags
conferences
-
Rhea-AI Summary
Ovid Therapeutics Inc. (NASDAQ: OVID) will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The webcast will be available on the Company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences
Rhea-AI Summary
Ovid Therapeutics Inc. (NASDAQ: OVID) presents new preclinical data supporting the potential of OV329 and OV350 programs for the treatment of epilepsies and treatment-resistant seizures at the 2023 American Epilepsy Society (AES) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
conferences
-
Rhea-AI Summary
Ovid Therapeutics Inc. reported business updates and financial results for Q3 2023. They received a $30 million payment from Ligand for the sale of a 13% interest in future royalties and milestone payments for soticlestat. The company extended its cash runway into 2026. Clinical trials for soticlestat remain on track, with regulatory filings anticipated in 2024. Ovid also announced expansions in its pipeline programs and expects to achieve five clinical and regulatory milestones in the next 15 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
earnings
-
Rhea-AI Summary
Ovid Therapeutics and Ligand Pharmaceuticals announce a partnership in which Ligand acquires a 13% portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of soticlestat. In return, Ovid will receive a $30 million payment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.13%
Tags
none
Rhea-AI Summary
Ovid Therapeutics to participate in Jefferies Inaugural Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
conferences
-
Rhea-AI Summary
Ovid Therapeutics Inc. will host a Research & Development Day investor event on October 2, 2023, providing updates on scientific strategy and clinical development plans. The event will feature presentations from recognized clinicians and academic thought leaders. In-person attendance is by invitation only.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
conferences
-
Rhea-AI Summary
Ovid Therapeutics to participate in panel presentation at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
conferences
Rhea-AI Summary
Ovid Therapeutics to participate in two upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.07%
Tags
conferences
Ovid Therapeutics Inc

Nasdaq:OVID

OVID Rankings

OVID Stock Data

215.67M
37.56M
15.99%
64.74%
5.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About OVID

ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/